Moreover, Parodis et al. found that the baseline levels of <1.5 ng/mL of serum BAFF can predict clinical response with a PPV of 92% and histological response with a PPV of 84% in a cohort of 52 proliferative LN patients [120]. This evidence concerns the gene TNFSF13B and lobular neoplasia.